Tesla Motors Inc (NASDAQ:TSLA) hasn’t changed the look of its Model S sedan since the sumptuous electric car first hit the market in 2012. Tesla Motors Inc (NASDAQ:TSLA) stock performance was -0.08% in last session and finished the day at $229.25. Traded volume was 5.17million shares in the last session and the average volume of the…
Earlier this month, Vivus Inc. (NASDAQ:VVUS) said it filed a patent-infringement lawsuit against Actavis PLC ( ACT ) alleging that the drug maker’s planned generic version of weight-loss drug Qsymia infringes its patents. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 3.97% in last session and finished the day at $5.50. Traded volume was 4.47million shares in the last…
Drugmaker Vivus Inc. (NASDAQ:VVUS) said Thursday it has filed a lawsuit against Actavis PLC and its affiliates in a New Jersey federal court over its bid with the U.S. Food and Drug Administration to sell a generic version of company’ prescription weight-loss drug Qsymia. VIVUS, Inc. (NASDAQ:VVUS) stock performance was -0.19% in last session and…
Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) announced that the U.S. Court of Appeals for the Federal Circuit today upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb’s entecavir compound claim of U.S. Patent No. 5,206,244 invalid. Teva’s ANDA for entecavir has received tentative approval from the U.S. Food…
InterMune, Inc. (NASDAQ:ITMN) on 27 May 2014 announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). InterMune Inc…
Investment analysts at JPMorgan Chase & Co. dropped their target price on shares of VIVUS (NASDAQ:VVUS) from $8.00 to $5.00 in a note issued to investors on Tuesday, Stock Ratings Network reports. JPMorgan Chase & Co.’s price target would indicate a potential downside of 10.15% from the company’s current price. VIVUS, Inc. (NASDAQ:VVUS)stock performance was…
